Skip to search formSkip to main contentSkip to account menu

TroVax

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

5T4 cancer vaccineCancer Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4
The recent approvals of immunotherapeutic agents (Sipuleucel-T and Ipilimumab) for the treatment of different solid tumors gave a… 
Review
2010
Review
2010
TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development
There has been renewed interest in developing vaccine and immunotherapy for the treatment of cancer. The oncofetal antigen, 5T4… 
Review
2010
Review
2010
Clinical and laboratory parameters associated with outcomes in patients with metastatic renal cell carcinoma treated with modified vaccinia Ankara delivering tumor antigen 5T4.
e13132 Background: Two separate studies have been conducted to study the efficacy of modified vaccinia Ankara delivering tumor… 
Review
2009
Review
2009
Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
2009
2009
Oxford BioMedica Handed Back Trovax® and Secures Ocular Disease Deal
2007
2007
Positive clinical data in Parkinson's and ischemia buoy gene therapy
2006
2006
A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: Phase II trial.
2574 Background: Oncofetal antigen 5T4 is expressed by most colorectal cancers. Administration of a vaccine combining a Modified… 
2005
2005
An open label phase II study of modified vaccinia ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: Safety and immunogenicity before, during and after chemotherapy
2578 Background: 5T4 is a tumour associated antigen that is widely expressed on the surface of most human adenocarcinomas… 
2004
2004
Technology evaluation: TroVax, Oxford BioMedica.
  • M. Reinis
  • Current opinion in molecular therapeutics (Print)
  • 2004
  • Corpus ID: 27636786
TroVax, a gene-based tumor vaccine that uses a poxvirus vector to deliver the tumor antigen gene 5T4, is under development by… 
2003
2003
961 Phase I study of escalating doses of TroVax® in patients wtih advanced colorectal cancer (CRC)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)